Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.18%-0.85 ppLife Sciences Tools & Services1.10%-0.54 ppManaged Health Care1.52%-0.31 ppHealth Care Equipment2.69%-0.28 ppBiotechnology2.15%-0.21 ppHealth Care Services0.54%-0.16 ppHealth Care Supplies0.11%-0.10 ppHealth Care Facilities0.20%-0.04 ppHealth Care Technology0.03%+0.03 ppHealth Care Distributors0.43%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.15%
Industry change · 12M
-0.21 pp
Biotechnology · contribution
-0.208 pp
Company participation
50%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Mar 2025 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals → REGN | United States | $59.6bn | 0.141% | -0.010 pp | -0.109 pp | -34.0% | No |
| Moderna → MRNA | United States | $10.9bn | 0.026% | -0.010 pp | -0.087 pp | -73.4% | No |
| Gilead Sciences → GILD | United States | $139.5bn | 0.331% | +0.070 pp | +0.078 pp | +58.7% | Yes |
| Biogen → BIIB | United States | $20.0bn | 0.048% | -0.003 pp | -0.039 pp | -36.5% | No |
| Amgen → AMGN | United States | $167.4bn | 0.397% | +0.080 pp | -0.025 pp | +12.9% | Yes |
| AbbVie → ABBV | United States | $369.9bn | 0.878% | +0.166 pp | -0.014 pp | +19.2% | Yes |
| Incyte → INCY | United States | $11.7bn | 0.028% | -0.002 pp | -0.008 pp | +6.3% | No |
| Vertex Pharmaceuticals → VRTX | United States | $124.5bn | 0.296% | +0.060 pp | -0.004 pp | +16.0% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.